首页 > 最新文献

Russian Journal of Transplantology and Artificial Organs最新文献

英文 中文
Intraperitoneal injection of cell-engineered pancreas in rats with experimental type i diabetes (preliminary results) 实验性i型糖尿病大鼠腹腔注射细胞工程胰腺(初步结果)
Pub Date : 2023-07-15 DOI: 10.15825/1995-1191-2023-2-107-117
A. S. Ponomareva, N. Baranova, A. Nikolskaya, L. A. Kirsanova, N. Onishchenko, Z. Z. Gonikova, G. N. Bubentsova, Е. A. Volkova, Y. Basok, V. Sevastianov
Creation of a bioartificial pancreas, including a cell-engineered construct (CEC) formed from pancreatic islets (islets of Langerhans) and a biocompatible matrix mimicking the native microenvironment of pancreatic tissue, is one of the approaches to the treatment of type 1 diabetes mellitus (T1D).Objective: to conduct preliminary in vivo studies of the functional efficacy of intraperitoneal injection of a cell-engineered pancreatic endocrine construct and a suspension of rat pancreatic islets in an experimental T1D model.Materials and methods. Tissue-specific scaffold was obtained by decellularization of human pancreatic fragments. The viability and functional activity of rat islets isolated with collagenase were determined. Experimental T1D was modeled by intraperitoneal injection of low-dose streptozotocin and incomplete Freund’s adjuvant into rats. The rats were intraperitoneally injected twice with pancreatic CEC (n = 2) or islet suspension (n = 1). Glucose levels in the blood and urine of the rats were assessed. Histological examination of organs (pancreas and kidneys) of the experimental animals was carried out.Results. After the first injection, blood glucose levels gradually decreased in all animals by more than 47% of the initial values; by follow-up day 24, the glucose level rose to the initial hyperglycemic values. After repeated administration, a 63.4% decrease in glycemic level was observed in the rats with pancreatic CEC and a 47.5% decrease in the one with islet suspension. At week 5 of the experiment, blood glucose levels gradually increased in all animals. At the same time, the glycemic index of the rat with injected pancreatic CEC was 62% lower than the glycemic index of the rat with injected islets.Conclusion. Allogeneic pancreatic islets in pancreatic CEC increase the duration of stable glycemic level in T1D rats.
生物人工胰腺的创建,包括由胰岛(朗格汉斯胰岛)和模拟胰腺组织原生微环境的生物相容性基质形成的细胞工程构建体(CEC),是治疗1型糖尿病(T1D)的方法之一。目的:在实验性T1D模型中,对腹腔注射细胞工程胰腺内分泌构建物和胰岛悬浮液对大鼠胰岛功能的影响进行初步体内研究。材料和方法。将人胰腺碎片脱细胞获得组织特异性支架。用胶原酶分离大鼠胰岛,测定其细胞活力和功能活性。采用腹腔注射低剂量链脲佐菌素和不完全弗氏佐剂的方法造模大鼠实验性T1D。大鼠腹腔注射胰腺CEC (n = 2)或胰岛悬浮液(n = 1)两次,评估大鼠血液和尿液中的葡萄糖水平。对实验动物各脏器(胰腺、肾脏)进行组织学检查。第一次注射后,所有动物的血糖水平逐渐下降,下降幅度超过初始值的47%;随访第24天,血糖水平上升至初始高血糖值。反复给药后,胰腺CEC大鼠血糖水平下降63.4%,胰岛悬浮大鼠血糖水平下降47.5%。实验第5周,所有动物的血糖水平逐渐升高。同时,注射胰腺CEC大鼠的血糖指数比注射胰岛大鼠的血糖指数低62%。胰腺CEC中的异体胰岛增加了T1D大鼠血糖水平稳定的持续时间。
{"title":"Intraperitoneal injection of cell-engineered pancreas in rats with experimental type i diabetes (preliminary results)","authors":"A. S. Ponomareva, N. Baranova, A. Nikolskaya, L. A. Kirsanova, N. Onishchenko, Z. Z. Gonikova, G. N. Bubentsova, Е. A. Volkova, Y. Basok, V. Sevastianov","doi":"10.15825/1995-1191-2023-2-107-117","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-2-107-117","url":null,"abstract":"Creation of a bioartificial pancreas, including a cell-engineered construct (CEC) formed from pancreatic islets (islets of Langerhans) and a biocompatible matrix mimicking the native microenvironment of pancreatic tissue, is one of the approaches to the treatment of type 1 diabetes mellitus (T1D).Objective: to conduct preliminary in vivo studies of the functional efficacy of intraperitoneal injection of a cell-engineered pancreatic endocrine construct and a suspension of rat pancreatic islets in an experimental T1D model.Materials and methods. Tissue-specific scaffold was obtained by decellularization of human pancreatic fragments. The viability and functional activity of rat islets isolated with collagenase were determined. Experimental T1D was modeled by intraperitoneal injection of low-dose streptozotocin and incomplete Freund’s adjuvant into rats. The rats were intraperitoneally injected twice with pancreatic CEC (n = 2) or islet suspension (n = 1). Glucose levels in the blood and urine of the rats were assessed. Histological examination of organs (pancreas and kidneys) of the experimental animals was carried out.Results. After the first injection, blood glucose levels gradually decreased in all animals by more than 47% of the initial values; by follow-up day 24, the glucose level rose to the initial hyperglycemic values. After repeated administration, a 63.4% decrease in glycemic level was observed in the rats with pancreatic CEC and a 47.5% decrease in the one with islet suspension. At week 5 of the experiment, blood glucose levels gradually increased in all animals. At the same time, the glycemic index of the rat with injected pancreatic CEC was 62% lower than the glycemic index of the rat with injected islets.Conclusion. Allogeneic pancreatic islets in pancreatic CEC increase the duration of stable glycemic level in T1D rats.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88347986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physical rehabilitation in pediatric organ recipients 小儿器官接受者的身体康复
Pub Date : 2023-07-11 DOI: 10.15825/1995-1191-2023-3-50-56
Т.Ю. Шелехова, О.М. Цирульникова, И.А. Лазарева, О.Е. Гичкун, Е.Е. Задябина, А.А. Шитова, T. Shelekhova, O. Tsirulnikova, I. A. Lazareva, O. Gichkun, E. E. Zadyabina, A. A. Shitova
The paper analyzes the literature on physical rehabilitation in transplantology. The medical and social aspects of rehabilitation and peculiarities of physical rehabilitation in child organ recipients are reflected. A rise in the number of organ recipients, including children, is noted. The role of physical rehabilitation in increasing the body’s adaptive reserves at the pre- and postoperative stage and improving the quality of life is described.
本文分析了有关移植医学中身体康复的文献。文中反映了康复的医学和社会方面以及儿童器官受者身体康复的特殊性。文章指出,包括儿童在内的器官受者人数不断增加。阐述了身体康复在增加术前和术后身体适应储备以及提高生活质量方面的作用。
{"title":"Physical rehabilitation in pediatric organ recipients","authors":"Т.Ю. Шелехова, О.М. Цирульникова, И.А. Лазарева, О.Е. Гичкун, Е.Е. Задябина, А.А. Шитова, T. Shelekhova, O. Tsirulnikova, I. A. Lazareva, O. Gichkun, E. E. Zadyabina, A. A. Shitova","doi":"10.15825/1995-1191-2023-3-50-56","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-3-50-56","url":null,"abstract":"The paper analyzes the literature on physical rehabilitation in transplantology. The medical and social aspects of rehabilitation and peculiarities of physical rehabilitation in child organ recipients are reflected. A rise in the number of organ recipients, including children, is noted. The role of physical rehabilitation in increasing the body’s adaptive reserves at the pre- and postoperative stage and improving the quality of life is described.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139360424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complex use of perfusion techniques in kidney transplantation from a donor with out-of-hospital cardiac arrest (clinical case) 院外心脏骤停供体肾移植中灌注技术的复杂应用(临床病例)
Pub Date : 2023-07-10 DOI: 10.15825/1995-1191-2023-3-113-121
A. Shabunin, M. Minina, P. Drozdov, I. Miloserdov, D. A. Saydulaev, V. M. Sevostyanov, E. A. Tenchurina
Objective: to present the successful experience with a donor with out-of-hospital cardiac arrest (OHCA) in whom a set of modern perfusion techniques was used to obtain kidneys suitable for transplantation.Materials and methods. Automatic chest compression was resumed in an OHCA donor (after biological death has been confirmed in the hospital) to maintain minimal perfusion under mechanical ventilation with 100% FiO2. With femoral vein cannulation, an extracorporeal circuit with a centrifuge pump and oxygenator was connected and abdominal normothermic regional perfusion was initiated. After 215 minutes, kidney was explanted under normothermic machine perfusion. Next, the left kidney was placed in the LifePort Kidney Transporter for hypothermic machine perfusion of donor kidneys. Perfusion time was 285 minutes. The right kidney was transplanted without additional ex-vivo perfusion.Results. Due to the complex use of perfusion techniques both in the donor body and ex-vivo, donor kidneys, after OHCA, with a total warm ischemia time of 110 minutes, were transplanted to recipients with good results. In the postoperative period, there was delayed function of the left and right renal grafts. The patients were discharged in a satisfactory condition under outpatient follow-up.Conclusion. The possibility and efficiency of organ donation after OHCA, facilitated by modern perfusion techniques and devices, open up a new perspective in addressing the organ shortage crisis.
目的:介绍对一名院外心脏骤停(OHCA)供体采用一套现代灌注技术获得适合移植的肾脏的成功经验。在 100% FiO2 的机械通气条件下,对一名 OHCA 供体(在医院确认生物学死亡后)恢复自动胸外按压,以维持最低限度的灌注。通过股静脉插管,连接了带有离心泵和氧合器的体外循环,并启动了腹腔常温区域灌注。215 分钟后,在常温机器灌注下取出肾脏。接着,将左肾放入 LifePort 肾脏转运器,对供体肾脏进行低温机器灌注。灌注时间为 285 分钟。右肾移植时没有进行额外的体外灌注。由于在供体体内和体外灌注技术的复杂应用,OHCA后的供肾在110分钟的热缺血时间内移植给了受体,效果良好。术后,左右肾移植物的功能出现延迟。结论:术后器官捐献的可能性和效率都很高。在现代灌注技术和设备的帮助下,心脏骤停后器官捐献的可能性和效率为解决器官短缺危机开辟了新的前景。
{"title":"Complex use of perfusion techniques in kidney transplantation from a donor with out-of-hospital cardiac arrest (clinical case)","authors":"A. Shabunin, M. Minina, P. Drozdov, I. Miloserdov, D. A. Saydulaev, V. M. Sevostyanov, E. A. Tenchurina","doi":"10.15825/1995-1191-2023-3-113-121","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-3-113-121","url":null,"abstract":"Objective: to present the successful experience with a donor with out-of-hospital cardiac arrest (OHCA) in whom a set of modern perfusion techniques was used to obtain kidneys suitable for transplantation.Materials and methods. Automatic chest compression was resumed in an OHCA donor (after biological death has been confirmed in the hospital) to maintain minimal perfusion under mechanical ventilation with 100% FiO2. With femoral vein cannulation, an extracorporeal circuit with a centrifuge pump and oxygenator was connected and abdominal normothermic regional perfusion was initiated. After 215 minutes, kidney was explanted under normothermic machine perfusion. Next, the left kidney was placed in the LifePort Kidney Transporter for hypothermic machine perfusion of donor kidneys. Perfusion time was 285 minutes. The right kidney was transplanted without additional ex-vivo perfusion.Results. Due to the complex use of perfusion techniques both in the donor body and ex-vivo, donor kidneys, after OHCA, with a total warm ischemia time of 110 minutes, were transplanted to recipients with good results. In the postoperative period, there was delayed function of the left and right renal grafts. The patients were discharged in a satisfactory condition under outpatient follow-up.Conclusion. The possibility and efficiency of organ donation after OHCA, facilitated by modern perfusion techniques and devices, open up a new perspective in addressing the organ shortage crisis.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139360957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experience of outpatient follow-up of heart transplant recipients at Shumakov center 舒马科夫中心心脏移植受者门诊随访经验
Pub Date : 2023-07-07 DOI: 10.15825/1995-1191-2023-3-68-75
I. I. Muminov, N. Koloskova, V. Poptsov, V. M. Zakharevich, N. Mozheiko, S. Sakhovsky, A. O. Shevchenko
Heart transplantation (HT) is considered the optimal therapy for end-stage heart failure. In recent years, the number of operations performed has been growing, which has led to a rise in the number of heart transplant recipients requiring outpatient follow-up.Objective: to evaluate the effectiveness of the model of dual personalized follow-up of heart transplant recipients in the consultative and diagnostic department of Shumakov National Medical Research Center of Transplantology and Artificial Organs.Materials and methods. The study included 1,436 patients under outpatient follow-up from January 2008 to December 2022. Recipient data, results of laboratory and instrumental examination methods, nature and frequency of complications at different follow-up periods were analyzed.Results: At the time of discharge from the hospital, 98.7% of patients had received triple-drug immunosuppressive therapy; 6 months later, methylprednisolone was discontinued in 72.2% of recipients. Mean tacrolimus level during the 1-year follow-up was 8.7 ± 2.7 ng/mL; in the period from 1 to 5 years of followup, the mean was 5.1 ± 2.4 ng/mL. At year 1 after transplantation, 23 (1.7%) recipients had been converted to everolimus; by the end of year 5 of follow-up, the number had increased to 8.6%. The most frequently detected complications during outpatient follow-up were: hypertension (48.65%), post-transplant diabetes mellitus (7.24%), nephropathy (35.97%), and malignant neoplasms (4.2%). Recipient survival, excluding in-hospital mortality, was 96.5%; and 88.0% at year 1 and 5 of follow-up, respectively.Conclusion: The dual personalized approach model for outpatient follow-up and treatment of heart transplant recipients will improve recipient survival and quality of life in the long-term post-HT period.
心脏移植(HT)被认为是治疗终末期心力衰竭的最佳疗法。近年来,手术数量不断增加,导致需要门诊随访的心脏移植受者人数上升。目的:评估舒马科夫国立移植与人工器官医学研究中心咨询诊断部门对心脏移植受者进行双重个性化随访模式的有效性。研究对象包括 2008 年 1 月至 2022 年 12 月期间接受门诊随访的 1436 名患者。对受者数据、实验室和仪器检查方法结果、不同随访期并发症的性质和频率进行了分析:出院时,98.7%的患者接受了三联免疫抑制剂治疗;6个月后,72.2%的受者停用了甲基强的松龙。随访1年期间,他克莫司的平均水平为8.7 ± 2.7纳克/毫升;随访1至5年期间,平均水平为5.1 ± 2.4纳克/毫升。移植后第1年,有23名受者(1.7%)改用依维莫司;随访第5年末,这一数字增至8.6%。门诊随访期间最常发现的并发症是:高血压(48.65%)、移植后糖尿病(7.24%)、肾病(35.97%)和恶性肿瘤(4.2%)。除去院内死亡率,接受者的存活率为96.5%;随访第1年和第5年的存活率分别为88.0%:结论:对心脏移植受者进行门诊随访和治疗的双重个性化方法模式将提高受者在心脏移植术后长期的生存率和生活质量。
{"title":"Experience of outpatient follow-up of heart transplant recipients at Shumakov center","authors":"I. I. Muminov, N. Koloskova, V. Poptsov, V. M. Zakharevich, N. Mozheiko, S. Sakhovsky, A. O. Shevchenko","doi":"10.15825/1995-1191-2023-3-68-75","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-3-68-75","url":null,"abstract":"Heart transplantation (HT) is considered the optimal therapy for end-stage heart failure. In recent years, the number of operations performed has been growing, which has led to a rise in the number of heart transplant recipients requiring outpatient follow-up.Objective: to evaluate the effectiveness of the model of dual personalized follow-up of heart transplant recipients in the consultative and diagnostic department of Shumakov National Medical Research Center of Transplantology and Artificial Organs.Materials and methods. The study included 1,436 patients under outpatient follow-up from January 2008 to December 2022. Recipient data, results of laboratory and instrumental examination methods, nature and frequency of complications at different follow-up periods were analyzed.Results: At the time of discharge from the hospital, 98.7% of patients had received triple-drug immunosuppressive therapy; 6 months later, methylprednisolone was discontinued in 72.2% of recipients. Mean tacrolimus level during the 1-year follow-up was 8.7 ± 2.7 ng/mL; in the period from 1 to 5 years of followup, the mean was 5.1 ± 2.4 ng/mL. At year 1 after transplantation, 23 (1.7%) recipients had been converted to everolimus; by the end of year 5 of follow-up, the number had increased to 8.6%. The most frequently detected complications during outpatient follow-up were: hypertension (48.65%), post-transplant diabetes mellitus (7.24%), nephropathy (35.97%), and malignant neoplasms (4.2%). Recipient survival, excluding in-hospital mortality, was 96.5%; and 88.0% at year 1 and 5 of follow-up, respectively.Conclusion: The dual personalized approach model for outpatient follow-up and treatment of heart transplant recipients will improve recipient survival and quality of life in the long-term post-HT period.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139361553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aortic valve replacement after previous TAVI 既往 TAVI 后的主动脉瓣置换术
Pub Date : 2023-07-07 DOI: 10.15825/1995-1191-2023-3-129-138
D. A. Titov, M. N. Sorkomov, D. Pursanova, M. I. Fedoseykina, S. Babenko, R. Muratov
Endovascular surgery for aortic valve defects has proven itself well in elderly patients with severe comorbidities competing with the underlying disease. However, the risk of dysfunction resulting from structural degeneration of bioprosthetic heart valve and prosthetic valve endocarditis remains high. Repeated surgeries are associated with complications, but open surgery is the only method of treatment in this group of patients.Objective: to describe a series of reinterventions for prosthetic valve dysfunction occurring after TAVI.Material and methods. From 2015 to 2022, at the Department of Emergency Surgery for Acquired Heart Diseases (Head, Professor R.M. Muratov), Bakulev Research Center for Cardiovascular Surgery, 6 reoperations were performed in patients who had previously undergone transcatheter aortic valve implantation (TAVI). The average age of patients at the time of TAVI and at the time of reoperation was 70.6 years (62–83) and 74.3 years (70–84), respectively. The EuroSCORE II predicted risk of mortality at the time of reintervention was 42.2% (21.7–87.6). The mean time to reoperation was 42 months. Indications for reoperation were early active prosthetic endocarditis (4 cases) and structural valve degeneration (2 cases).Results. At the hospital stage, 1 patient died of acute heart failure; the operation was performed for vital indications in conditions of extreme initial severity. In three patients, the early postoperative period was uneventful. One patient required intra-aortic balloon counterpulsation (IABP) due to heart failure, and 1 patient was implanted with permanent pacemaker. The average time of hospitalization was 14 days. Patients with active prosthetic endocarditis received a 6-week course of antibiotic therapy. The function of the implanted valves was satisfactory.Conclusions. Aortic valve replacement after previous TAVI is an emergency operation and represents the only way to treat valve dysfunction. Under active prosthetic endocarditis, timely surgery can save this patient cohort.
主动脉瓣缺损的血管内手术在患有严重并发症的老年患者中已被证明效果良好。然而,生物人工心脏瓣膜结构退化和人工瓣膜心内膜炎导致功能障碍的风险仍然很高。重复手术与并发症有关,但开放手术是这类患者的唯一治疗方法。目的:描述TAVI术后发生的人工瓣膜功能障碍的一系列再介入治疗。2015年至2022年,巴库廖夫心血管外科研究中心后天性心脏病急诊外科(主任:R.M. Muratov教授)对曾接受过经导管主动脉瓣植入术(TAVI)的患者进行了6次再手术。患者接受经导管主动脉瓣植入术和再次手术时的平均年龄分别为 70.6 岁(62-83 岁)和 74.3 岁(70-84 岁)。再介入时的EuroSCORE II预测死亡风险为42.2%(21.7-87.6)。再次手术的平均时间为 42 个月。再次手术的指征为早期活动性人工心内膜炎(4例)和结构性瓣膜退化(2例)。在医院阶段,1名患者死于急性心力衰竭;手术是在最初病情极其严重的情况下,出于重要的适应症而进行的。三名患者的术后早期并无大碍。一名患者因心衰需要主动脉内球囊反搏器(IABP),一名患者植入了永久起搏器。平均住院时间为 14 天。活动性人工心内膜炎患者接受了为期6周的抗生素治疗。植入瓣膜的功能令人满意。主动脉瓣置换术是一种紧急手术,是治疗瓣膜功能障碍的唯一方法。在人工心内膜炎活跃的情况下,及时手术可以挽救这部分患者。
{"title":"Aortic valve replacement after previous TAVI","authors":"D. A. Titov, M. N. Sorkomov, D. Pursanova, M. I. Fedoseykina, S. Babenko, R. Muratov","doi":"10.15825/1995-1191-2023-3-129-138","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-3-129-138","url":null,"abstract":"Endovascular surgery for aortic valve defects has proven itself well in elderly patients with severe comorbidities competing with the underlying disease. However, the risk of dysfunction resulting from structural degeneration of bioprosthetic heart valve and prosthetic valve endocarditis remains high. Repeated surgeries are associated with complications, but open surgery is the only method of treatment in this group of patients.Objective: to describe a series of reinterventions for prosthetic valve dysfunction occurring after TAVI.Material and methods. From 2015 to 2022, at the Department of Emergency Surgery for Acquired Heart Diseases (Head, Professor R.M. Muratov), Bakulev Research Center for Cardiovascular Surgery, 6 reoperations were performed in patients who had previously undergone transcatheter aortic valve implantation (TAVI). The average age of patients at the time of TAVI and at the time of reoperation was 70.6 years (62–83) and 74.3 years (70–84), respectively. The EuroSCORE II predicted risk of mortality at the time of reintervention was 42.2% (21.7–87.6). The mean time to reoperation was 42 months. Indications for reoperation were early active prosthetic endocarditis (4 cases) and structural valve degeneration (2 cases).Results. At the hospital stage, 1 patient died of acute heart failure; the operation was performed for vital indications in conditions of extreme initial severity. In three patients, the early postoperative period was uneventful. One patient required intra-aortic balloon counterpulsation (IABP) due to heart failure, and 1 patient was implanted with permanent pacemaker. The average time of hospitalization was 14 days. Patients with active prosthetic endocarditis received a 6-week course of antibiotic therapy. The function of the implanted valves was satisfactory.Conclusions. Aortic valve replacement after previous TAVI is an emergency operation and represents the only way to treat valve dysfunction. Under active prosthetic endocarditis, timely surgery can save this patient cohort.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139362098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric mechanical circulatory support: pathophysiology of pediatric hemostasis and postoperative management algorithms 小儿机械循环支持:小儿止血的病理生理学和术后处理算法
Pub Date : 2023-04-08 DOI: 10.15825/1995-1191-2023-1-90-98
N. Koloskova, T. A. Khalilulin, D. Ryabtsev, V. Poptsov
Chronic heart failure (CHF) against the background of congenital heart disease, mostly in early childhood, or various forms of cardiomyopathies, more common in teenage age, represents an important cause of morbidity and mortality in the pediatric population [1, 2]. Due to the increase in the number of patients suffering from refractory end-stage CHF over the last two decades, and the current shortage of donor organs in pediatric practice, the issue of long-term mechanical circulatory support (MCS) is becoming increasingly a pressing problem. Patient management is a multidisciplinary task, since prolonged use of anticoagulant and antiplatelet therapy to prevent ventricular thrombosis has potentially life-threatening complications - acute hemorrhagic stroke and bleeding of varying severity.
慢性心力衰竭(CHF)以先天性心脏病为背景,主要发生在幼儿期,或各种形式的心肌病,更常见于青少年期,是儿科人群发病率和死亡率的重要原因[1,2]。在过去的二十年中,由于难治性终末期CHF患者数量的增加,以及目前儿科实践中供体器官的短缺,长期机械循环支持(MCS)问题日益成为一个紧迫的问题。患者管理是一项多学科的任务,因为长期使用抗凝和抗血小板治疗来预防心室血栓形成有潜在的危及生命的并发症-急性出血性中风和不同严重程度的出血。
{"title":"Pediatric mechanical circulatory support: pathophysiology of pediatric hemostasis and postoperative management algorithms","authors":"N. Koloskova, T. A. Khalilulin, D. Ryabtsev, V. Poptsov","doi":"10.15825/1995-1191-2023-1-90-98","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-1-90-98","url":null,"abstract":"Chronic heart failure (CHF) against the background of congenital heart disease, mostly in early childhood, or various forms of cardiomyopathies, more common in teenage age, represents an important cause of morbidity and mortality in the pediatric population [1, 2]. Due to the increase in the number of patients suffering from refractory end-stage CHF over the last two decades, and the current shortage of donor organs in pediatric practice, the issue of long-term mechanical circulatory support (MCS) is becoming increasingly a pressing problem. Patient management is a multidisciplinary task, since prolonged use of anticoagulant and antiplatelet therapy to prevent ventricular thrombosis has potentially life-threatening complications - acute hemorrhagic stroke and bleeding of varying severity.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87556495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biological and functional properties of human umbilical cord-derived lyophilized tissue-engineered matrices 人脐带源性冻干组织工程基质的生物学和功能特性
Pub Date : 2023-04-08 DOI: 10.15825/1995-1191-2023-1-113-122
A. A. Kondratenko, L. Kalyuzhnaya, D. Tovpeko, V. S. Sheveleva, R. Glushakov
The use of tissue-engineered products (TEP) from decellularized extracellular matrix (dECM) to treat deep skin lesions is a tissue engineering method that promotes regenerative healing. Cell-free preparations reproduce the hierarchical complexity of tissues, mimic structural, biochemical and mechanical signals that are necessary to attract cells, and are a source of bioactive molecules. The human umbilical cord biomaterial has a fetal phenotype with extra-embryonic origin, and therefore is available and has no ethical limitations in its use. The tissue engineering laboratory at Kirov Military Medical Academy developed and patented a TEP from the highly regenerative human umbilical cord in the form of matrix and hydrogel matrix. To study its regenerative potential, lyophilisates of tissue-engineered solid-state and hydrogel matrices were implanted around mini pig fullthickness wounds in vivo. The external signs of inflammatory response and the histological images of biopsy specimens from the lyophilizate implantation areas were analyzed. The effect of nutrient media, «conditioned» with lyophilizates of both matrices, on the viability and migration activity of fibroblast-like cells, isolated from mini pig skin, was investigated. The matrix lyophilisates showed good biocompatibility and bioactivity in in vitro and in vivo experiments. Implantation of the samples promoted faster formation of mature epidermis compared to the control.
使用来自脱细胞细胞外基质(dECM)的组织工程产品(TEP)治疗深层皮肤病变是一种促进再生愈合的组织工程方法。无细胞制剂再现了组织的层次复杂性,模拟了吸引细胞所必需的结构、生化和机械信号,并且是生物活性分子的来源。人类脐带生物材料具有胚胎外起源的胎儿表型,因此是可用的,并且在其使用中没有伦理限制。基洛夫军事医学学院的组织工程实验室从高度再生的人类脐带中开发了一种TEP,并申请了专利,该TEP以基质和水凝胶基质的形式存在。为了研究其再生潜力,将组织工程固体和水凝胶基质冻干液植入小型猪全层伤口周围。分析了炎症反应的外部征象和冻干植入区活检标本的组织学图像。研究了用两种基质的冻干物“调理”的营养培养基对从迷你猪皮肤中分离的成纤维细胞样细胞的活力和迁移活性的影响。体外和体内实验表明基质冻干细胞具有良好的生物相容性和生物活性。与对照相比,植入样品促进了成熟表皮的更快形成。
{"title":"Biological and functional properties of human umbilical cord-derived lyophilized tissue-engineered matrices","authors":"A. A. Kondratenko, L. Kalyuzhnaya, D. Tovpeko, V. S. Sheveleva, R. Glushakov","doi":"10.15825/1995-1191-2023-1-113-122","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-1-113-122","url":null,"abstract":"The use of tissue-engineered products (TEP) from decellularized extracellular matrix (dECM) to treat deep skin lesions is a tissue engineering method that promotes regenerative healing. Cell-free preparations reproduce the hierarchical complexity of tissues, mimic structural, biochemical and mechanical signals that are necessary to attract cells, and are a source of bioactive molecules. The human umbilical cord biomaterial has a fetal phenotype with extra-embryonic origin, and therefore is available and has no ethical limitations in its use. The tissue engineering laboratory at Kirov Military Medical Academy developed and patented a TEP from the highly regenerative human umbilical cord in the form of matrix and hydrogel matrix. To study its regenerative potential, lyophilisates of tissue-engineered solid-state and hydrogel matrices were implanted around mini pig fullthickness wounds in vivo. The external signs of inflammatory response and the histological images of biopsy specimens from the lyophilizate implantation areas were analyzed. The effect of nutrient media, «conditioned» with lyophilizates of both matrices, on the viability and migration activity of fibroblast-like cells, isolated from mini pig skin, was investigated. The matrix lyophilisates showed good biocompatibility and bioactivity in in vitro and in vivo experiments. Implantation of the samples promoted faster formation of mature epidermis compared to the control.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90298503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Mid-term and long-term outcomes following heart transplantation with prolonged cold ischemia 长时间冷缺血心脏移植的中期和长期预后
Pub Date : 2023-04-08 DOI: 10.15825/1995-1191-2023-1-99-105
A. Fomichev, V. Poptsov, D. Sirota, M. Zhulkov, A. Edemskiy, А. V. Protopopov, V. Y. Kliver, A. Skokova, A. Chernyavskiy, D. Khvan, K. Agayeva
Objective: comparative analysis of long-term outcomes following heart transplantation (HT) with prolonged and short cold ischemia.Materials and methods. We analyzed the data of 29 orthotopic HT with >4 hours of cold ischemia. The transplant surgery was performed at Meshalkin National Medical Research Center between 2013 and the present time. Organs were obtained from donors from other regions. The control group consisted of 29 HTs with cold ischemia <4 hours, performed in the same period. The minimum distance between the transplant center and the donor base was about 250 km (Barnaul); the maximum distance was about 850 km (Krasnoyarsk). Recipient survival and postoperative peculiarities were analyzed.Results. In-hospital survival in the prolonged cold ischemia group was 89.7% (n = 26) with 3 deaths (10.3%). In the second group (<240 min), in-hospital survival was 79.3% (n = 23) with 6 (20.7%) deaths. The Kaplan-Meier survival analysis showed no difference between the groups (Log-Rank Test, P 1/4 0.59). In addition, cold ischemia time did not increase the risk of graft rejection and the risk of transplant coronary artery disease (TCAD).Conclusion. HT with cold ischemia >4 hours did not have worse outcomes than in short graft ischemia. This provides grounds for further accumulation of experience in the use of heart donors from remote locations.
目的:比较分析心脏移植术后长时间和短时间冷缺血的远期预后。材料和方法。我们分析了29例原位HT伴bbbb4小时冷缺血的数据。移植手术于2013年至今在Meshalkin国家医学研究中心进行。器官来自其他地区的捐赠者。对照组29例HTs冷缺血4小时的预后不差于短缺血组。这为进一步积累利用来自偏远地区的心脏捐献者的经验提供了依据。
{"title":"Mid-term and long-term outcomes following heart transplantation with prolonged cold ischemia","authors":"A. Fomichev, V. Poptsov, D. Sirota, M. Zhulkov, A. Edemskiy, А. V. Protopopov, V. Y. Kliver, A. Skokova, A. Chernyavskiy, D. Khvan, K. Agayeva","doi":"10.15825/1995-1191-2023-1-99-105","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-1-99-105","url":null,"abstract":"Objective: comparative analysis of long-term outcomes following heart transplantation (HT) with prolonged and short cold ischemia.Materials and methods. We analyzed the data of 29 orthotopic HT with >4 hours of cold ischemia. The transplant surgery was performed at Meshalkin National Medical Research Center between 2013 and the present time. Organs were obtained from donors from other regions. The control group consisted of 29 HTs with cold ischemia <4 hours, performed in the same period. The minimum distance between the transplant center and the donor base was about 250 km (Barnaul); the maximum distance was about 850 km (Krasnoyarsk). Recipient survival and postoperative peculiarities were analyzed.Results. In-hospital survival in the prolonged cold ischemia group was 89.7% (n = 26) with 3 deaths (10.3%). In the second group (<240 min), in-hospital survival was 79.3% (n = 23) with 6 (20.7%) deaths. The Kaplan-Meier survival analysis showed no difference between the groups (Log-Rank Test, P 1/4 0.59). In addition, cold ischemia time did not increase the risk of graft rejection and the risk of transplant coronary artery disease (TCAD).Conclusion. HT with cold ischemia >4 hours did not have worse outcomes than in short graft ischemia. This provides grounds for further accumulation of experience in the use of heart donors from remote locations.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91405214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Experience with percutaneous right ventricular support in the early post-left ventricular assist device implantation period (clinical case report and literature reviews) 左室辅助装置植入后早期经皮右室支持的体会(临床病例报告及文献复习)
Pub Date : 2023-04-08 DOI: 10.15825/1995-1191-2023-1-77-89
V. Poptsov, E. Spirina, D. Ryabtsev, A. K. Solodovnikova, A. S. Epremian
Implantable left ventricular assist device (LVAD) is a state-of-the-art treatment for adults and children with end-stage heart failure. The early and late period after LVAD implantation can be severely complicated. Right ventricular failure (RVF) still remains a common complication after LVAD implantation. RVF is the cause of reduced post-implant survival. We suggest that an additional temporary or permanent right ventricular assist device (RVAD) is an effective treatment for LVAD-associated RVF. In this clinical case report, we describe the medical history of a pediatric patient (14 years old) with severe heart failure (PediMACS Level 1) against a background of dilated cardiomyopathy. The patient required peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO) prior to urgent LVAD (HM3) implantation. In the early post-LVAD implantation (1 POD) period, the patient presented with hemodynamic and echocardiographic events of acute RVF that was resistant to drug therapy (inotropic/vasopressor support, iNO) and required mechanical circulatory support (MCS) with a preoperatively implanted VA-ECMO. In the LVAD-associated RVF scenario, VA-ECMO as a means of total cardiac bypass is a non-physiological MCS method and, therefore, undesirable. In this clinical situation, our solution was to use a paracorporeal centrifugal blood pump for temporary right heart support. A RVAD was assembled using percutaneous cannulation in two sites and a modification of the pre-existing VA-ECMO circuit. For RVAD, we used an ECMO cannula previously installed through the femoral vein (26 F) and added a reverse venous cannula (22 F) through the right internal jugular vein into the pulmonary trunk. To facilitate the passage of the return cannula into the pulmonary artery, we used a contralateral sheath (6 F, 40 cm) and an Amplatz Super Stiff guidewire under radiological control. The oxygenator was removed from the circuit on day 2 of RVAD. Central hemodynamics (reduction in right atrial pressure (RAP) to 10 mm Hg, increase in pulmonary capillary wedge pressure (PCWP) to 14 mm Hg), as well as right ventricular (RV) and left ventricular (LV) volume characteristics all improved. These observations allowed us to optimize the performance of the implantable LVAD (increase in flow rate to 4.2 l/min or 2.1 l/min/m2). The duration of paracorporeal RVAD after LVAD implantation was 7 days with an average flow rate of 2.3 ± 0.2 l/min. Postoperative treatment in the intensive care unit (ICU) lasted for 15 days. The patient was discharged from the hospital on postoperative day 34.
植入式左心室辅助装置(LVAD)是一种最先进的治疗成人和儿童终末期心力衰竭。LVAD植入后的早期和后期可能严重复杂。右心室衰竭(RVF)仍然是LVAD植入后常见的并发症。裂谷热是导致植入后存活率降低的原因。我们建议额外的临时或永久性右心室辅助装置(RVAD)是lvad相关RVF的有效治疗方法。在这个临床病例报告中,我们描述了一名14岁的儿童患者的病史,他患有严重的心力衰竭(PediMACS 1级),背景是扩张性心肌病。在紧急LVAD (HM3)植入之前,患者需要外周静脉体外膜氧合(VA-ECMO)。在lvad植入后早期(1 POD)期间,患者出现急性裂谷热的血流动力学和超声心动图事件,对药物治疗(肌力/血管加压支持,iNO)有耐药性,需要术前植入VA-ECMO的机械循环支持(MCS)。在lvad相关的RVF情况下,VA-ECMO作为全心搭桥的一种非生理性MCS方法,因此是不可取的。在这种临床情况下,我们的解决方案是使用一个体外离心血泵来临时支持右心脏。RVAD通过两个部位的经皮插管和预先存在的VA-ECMO回路的修改组装。对于RVAD,我们使用了先前通过股静脉(26 F)安装的ECMO套管,并通过右颈内静脉进入肺动脉干添加了一个反向静脉套管(22 F)。为了方便插管进入肺动脉,我们在放射控制下使用对侧鞘(6 F, 40 cm)和Amplatz Super Stiff导丝。在RVAD第2天将氧合器从回路中取出。中心血流动力学(右房压(RAP)降至10 mm Hg,肺毛细血管楔压(PCWP)升高至14 mm Hg),右心室(RV)和左心室(LV)容积特性均改善。这些观察结果使我们能够优化植入式LVAD的性能(将流量增加到4.2 l/min或2.1 l/min/m2)。副躯体RVAD植入后持续时间为7 d,平均流量为2.3±0.2 l/min。术后在重症监护室(ICU)治疗15天。患者于术后第34天出院。
{"title":"Experience with percutaneous right ventricular support in the early post-left ventricular assist device implantation period (clinical case report and literature reviews)","authors":"V. Poptsov, E. Spirina, D. Ryabtsev, A. K. Solodovnikova, A. S. Epremian","doi":"10.15825/1995-1191-2023-1-77-89","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-1-77-89","url":null,"abstract":"Implantable left ventricular assist device (LVAD) is a state-of-the-art treatment for adults and children with end-stage heart failure. The early and late period after LVAD implantation can be severely complicated. Right ventricular failure (RVF) still remains a common complication after LVAD implantation. RVF is the cause of reduced post-implant survival. We suggest that an additional temporary or permanent right ventricular assist device (RVAD) is an effective treatment for LVAD-associated RVF. In this clinical case report, we describe the medical history of a pediatric patient (14 years old) with severe heart failure (PediMACS Level 1) against a background of dilated cardiomyopathy. The patient required peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO) prior to urgent LVAD (HM3) implantation. In the early post-LVAD implantation (1 POD) period, the patient presented with hemodynamic and echocardiographic events of acute RVF that was resistant to drug therapy (inotropic/vasopressor support, iNO) and required mechanical circulatory support (MCS) with a preoperatively implanted VA-ECMO. In the LVAD-associated RVF scenario, VA-ECMO as a means of total cardiac bypass is a non-physiological MCS method and, therefore, undesirable. In this clinical situation, our solution was to use a paracorporeal centrifugal blood pump for temporary right heart support. A RVAD was assembled using percutaneous cannulation in two sites and a modification of the pre-existing VA-ECMO circuit. For RVAD, we used an ECMO cannula previously installed through the femoral vein (26 F) and added a reverse venous cannula (22 F) through the right internal jugular vein into the pulmonary trunk. To facilitate the passage of the return cannula into the pulmonary artery, we used a contralateral sheath (6 F, 40 cm) and an Amplatz Super Stiff guidewire under radiological control. The oxygenator was removed from the circuit on day 2 of RVAD. Central hemodynamics (reduction in right atrial pressure (RAP) to 10 mm Hg, increase in pulmonary capillary wedge pressure (PCWP) to 14 mm Hg), as well as right ventricular (RV) and left ventricular (LV) volume characteristics all improved. These observations allowed us to optimize the performance of the implantable LVAD (increase in flow rate to 4.2 l/min or 2.1 l/min/m2). The duration of paracorporeal RVAD after LVAD implantation was 7 days with an average flow rate of 2.3 ± 0.2 l/min. Postoperative treatment in the intensive care unit (ICU) lasted for 15 days. The patient was discharged from the hospital on postoperative day 34.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88614269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of the quality of life of organ reoipients based on the results of the First Russian transplant games 基于第一届俄罗斯移植比赛结果的器官移植者生活质量评估
Pub Date : 2023-04-08 DOI: 10.15825/1995-1191-2023-1-62-67
Objective: to evaluate the role of physical activity (at sports games) in improving the quality of life of organ recipients.Materials and methods. We examined 42 adult lung, heart, kidney and liver recipients, and patients undergoing renal replacement therapy (mean age 42.6 ± 12.09 years) - participants of the First Russian Transplant Games. The results were analyzed. Quality of life of the recipients was assessed using the nonspecific SF-36 questionnaire.Results. After solid organ transplantation, the interviewed recipients answered that they try to lead an active lifestyle, to engage in accessible physical activities, and to participate in sports events intended for organ recipients. Assessment of the quality of life according to the SF-36 questionnaire showed that all the participants had high scores in terms of the physical and psychological component, which is associated with regular physical training and sports. Conclusion. Physical exercise and active participation in sports activities are an important component in the socialization and rehabilitation of organ recipients. These two factors also improve the psychological and physical components of the quality of life of the recipients.
目的:评价体育活动(体育比赛)对提高器官受者生活质量的作用。材料和方法。我们检查了42名成人肺、心、肾和肝受体,以及接受肾脏替代治疗的患者(平均年龄42.6±12.09岁)-第一届俄罗斯移植运动会的参与者。对结果进行分析。使用非特异性SF-36问卷评估接受者的生活质量。接受实体器官移植后,接受采访的受者回答说,他们努力过积极的生活方式,从事无障碍的体育活动,参加为器官受者举办的体育赛事。根据SF-36问卷对生活质量进行的评估显示,所有参与者在身体和心理方面的得分都很高,这与定期的体育训练和运动有关。结论。体育锻炼和积极参加体育活动是器官受者社会化和康复的重要组成部分。这两个因素也提高了接受者的心理和生理组成部分的生活质量。
{"title":"Assessment of the quality of life of organ reoipients based on the results of the First Russian transplant games","authors":"","doi":"10.15825/1995-1191-2023-1-62-67","DOIUrl":"https://doi.org/10.15825/1995-1191-2023-1-62-67","url":null,"abstract":"Objective: to evaluate the role of physical activity (at sports games) in improving the quality of life of organ recipients.Materials and methods. We examined 42 adult lung, heart, kidney and liver recipients, and patients undergoing renal replacement therapy (mean age 42.6 ± 12.09 years) - participants of the First Russian Transplant Games. The results were analyzed. Quality of life of the recipients was assessed using the nonspecific SF-36 questionnaire.Results. After solid organ transplantation, the interviewed recipients answered that they try to lead an active lifestyle, to engage in accessible physical activities, and to participate in sports events intended for organ recipients. Assessment of the quality of life according to the SF-36 questionnaire showed that all the participants had high scores in terms of the physical and psychological component, which is associated with regular physical training and sports. Conclusion. Physical exercise and active participation in sports activities are an important component in the socialization and rehabilitation of organ recipients. These two factors also improve the psychological and physical components of the quality of life of the recipients.","PeriodicalId":21400,"journal":{"name":"Russian Journal of Transplantology and Artificial Organs","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74186155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Russian Journal of Transplantology and Artificial Organs
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1